437 related articles for article (PubMed ID: 33892049)
1. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
[TBL] [Abstract][Full Text] [Related]
2. Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination.
Walia A; Sun Y; Acharya NR
JAMA Ophthalmol; 2024 Mar; 142(3):249-256. PubMed ID: 38358762
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
Sun Y; Jackson K; Dalmon CA; Shapiro BL; Nie S; Wong C; Arnold BF; Porco TC; Acharya NR
Vaccine; 2021 Jun; 39(29):3974-3982. PubMed ID: 34116874
[TBL] [Abstract][Full Text] [Related]
4. Incidence Rate of Herpes Zoster Ophthalmicus: A Retrospective Cohort Study from 1994 through 2018.
Kong CL; Thompson RR; Porco TC; Kim E; Acharya NR
Ophthalmology; 2020 Mar; 127(3):324-330. PubMed ID: 31668889
[TBL] [Abstract][Full Text] [Related]
5. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
[TBL] [Abstract][Full Text] [Related]
6. Herpes Zoster Ophthalmicus Review and Prevention.
Davis AR; Sheppard J
Eye Contact Lens; 2019 Sep; 45(5):286-291. PubMed ID: 30844951
[TBL] [Abstract][Full Text] [Related]
7. Seasonality of herpes zoster and herpes zoster ophthalmicus.
Berlinberg EJ; Kim E; Deiner MS; Patterson C; Porco TC; Acharya NR
J Clin Virol; 2020 May; 126():104306. PubMed ID: 32151977
[TBL] [Abstract][Full Text] [Related]
8. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
9. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.
Zhang J; Xie F; Delzell E; Chen L; Winthrop KL; Lewis JD; Saag KG; Baddley JW; Curtis JR
JAMA; 2012 Jul; 308(1):43-9. PubMed ID: 22760290
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study.
Sun Y; Kim E; Kong CL; Arnold BF; Porco TC; Acharya NR
Clin Infect Dis; 2021 Sep; 73(6):949-956. PubMed ID: 33580245
[TBL] [Abstract][Full Text] [Related]
11. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis.
Mbinta JF; Nguyen BP; Awuni PMA; Paynter J; Simpson CR
Lancet Healthy Longev; 2022 Apr; 3(4):e263-e275. PubMed ID: 36098300
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
13. Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.
Litt J; Cunningham AL; Arnalich-Montiel F; Parikh R
Infect Dis Ther; 2024 Jun; ():. PubMed ID: 38834857
[TBL] [Abstract][Full Text] [Related]
14. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
15. Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study.
Borkar DS; Tham VM; Esterberg E; Ray KJ; Vinoya AC; Parker JV; Uchida A; Acharya NR
Ophthalmology; 2013 Mar; 120(3):451-456. PubMed ID: 23207173
[TBL] [Abstract][Full Text] [Related]
16. Herpes zoster ophthalmicus: declining age at presentation.
Davies EC; Pavan-Langston D; Chodosh J
Br J Ophthalmol; 2016 Mar; 100(3):312-4. PubMed ID: 26178905
[TBL] [Abstract][Full Text] [Related]
17. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity.
Liesegang TJ
Ophthalmology; 2008 Feb; 115(2 Suppl):S3-12. PubMed ID: 18243930
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records.
Klein NP; Bartlett J; Fireman B; Marks MA; Hansen J; Lewis E; Aukes L; Saddier P
BMJ; 2023 Nov; 383():e076321. PubMed ID: 37940142
[TBL] [Abstract][Full Text] [Related]
19. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Zoster Vaccine [RZV] is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study.
Desai A; Hashash JG; Kochhar GS; Hayney MS; Caldera F; Farraye FA
J Crohns Colitis; 2024 Jun; 18(6):828-835. PubMed ID: 38224526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
